Compare CDMOs with oral solid dose manufacturing capabilities for tablets, capsules, and modified-release products. Filter by batch size, coating technology, and regulatory approvals.
364 companies listed
Tablets and capsules are the workhorse of pharma, roughly 60% of all drug products, so "oral solid dose CDMO" returns a crowded field. The differences that matter are technical, not marketing. Your API's flow and compressibility decide the granulation route: direct compression if it behaves, wet or dry granulation if it doesn't. A shop built for high-shear wet granulation isn't automatically the right home for a moisture-sensitive compound that needs roller compaction. Then there's scale. A CDMO that runs elegant 5,000-tablet clinical batches may not hold content uniformity at two million tablets a day. Heading toward extended- or delayed-release? Confirm the coating and multiparticulate expertise before you commit. Potent compound? Check the containment band (OEB) of the suite you'd actually run in. 364 CDMOs here list oral solid dose. Filter by batch size, coating technology, and regulatory market.
Oral solid dose (OSD) manufacturing is the highest-volume pharmaceutical manufacturing segment. Tablets and capsules account for approximately 60% of all drug products. The manufacturing process includes blending, granulation (wet or dry), compression or encapsulation, coating, and packaging. CDMOs range from small clinical-batch specialists to high-volume commercial manufacturers producing millions of units per day.
Modified-release technologies differentiate premium OSD CDMOs. Extended-release, delayed-release, and pulsatile-release formulations require specialized equipment and expertise in polymer coating, matrix systems, osmotic delivery, and multiparticulate approaches (pellets in capsules). These formulations improve patient compliance and can extend product lifecycle.
Latvia
Olpha (formerly Olainfarm JSC) is the leading pharmaceutical manufacturer in Latvia with over 50 years of experience and approximately 850 employees. The company produces finished dosage forms, active pharmaceutical ingredients, and intermediates across 10 therapeutic groups with a portfolio of more than 60 drug forms and 25 APIs. Olpha offers contract manufacturing and pharmaceutical co-development services, and exports to more than 60 markets. The company recently rebranded and aims to become a European top 10 pharmaceutical company.
Turkey
Onko Ilac Sanayi ve Ticaret A.S. is a Turkish pharmaceutical company offering contract manufacturing and out-licensing services. The company manufactures finished dosage form pharmaceutical products including oncology drugs (fingolimod, pemetrexed, temozolomide, abiraterone) and other therapeutic areas, exhibiting regularly at CPHI events.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.